MORRISTOWN, N.J. Actavis and Sagent Pharmaceuticals have agreed to develop and market a group of injectable drugs in the United States, Actavis announced.
Under the agreement, Actavis will develop the drugs, seek Food and Drug Administration approval for them and supply them, while Sagent will market them. Financial terms of the deal were not disclosed.
“Actavis’ impressive injectable pipeline, substantial development and supply capabilities and excellent record of execution make Actavis an outstanding partner Sagent,” Sagent CEO and board chairman Jeffrey Yordon said in a statement. “This collaboration complements Sagent’s strategy by quickly adding products to our marketed portfolio, and we look forward to working with Actavis to expand our collective portfolio.”